IFNG and neoplasm: Vaccine-boosted CAR-T cells trigger robust recruitment and activation of DCs in the tumor, which in turn secrete IL-12 that, together with the autocrine effect of IFN-γ, enhances CAR T-cell anti-tumor activity (Figure 7O), leading to pronounced endogenous T-cell priming and induction of enhanced effector programs in endogenous T-cells that infiltrate tumors.